# Amgen Inc. (AMGN) · Edgar & Edgarette company card

> Amgen (AMGN) grew revenue 10.0% in FY2025 to $36.8 billion, operating margin 24.7% against a -15.8% median for biological products, (no diagnostic substances), equity 9.6% of assets, and dividend per share up 9 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 318154 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AMGN) · [JSON](https://www.pops4.com/boards/company/AMGN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $36.8B |
| Revenue growth, 1 year | 10.0% |
| Revenue growth per year | 9.1% |
| Operating margin | 24.7% (prior year 21.7%) |
| Net margin | 21.0% |
| Operating cash flow | $10.0B |
| Capital spending | $1.9B |
| Free cash flow | $8.1B |
| Cash | $9.1B |
| Long-term debt | $54.6B |
| Total assets | $90.6B |
| Total equity | $8.7B |
| Equity ÷ assets | 9.6% |
| Return on equity | 89.1% |
| Dividend per share | $9.66 |
| Dividend years rising | 9 |

## Readings, computed from those figures

- Altman Z: 0.14 (distress zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.26 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · filed cybersecurity incident in the last 12 months
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $36.8B (FY2025), total debt $54.6B. Experience: revenue up 10.0% on the year, up 9.1% a year over 4 years; operating margin 24.7%, up from 21.7%. Soundness: equity 9.6% of assets, return on equity 89.1%, payout 66.5% of profit, dividend per share up 9 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $36.0B and $43.1B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $33.3B to $46.3B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 24.7% against a -15.8% median; growth 10.0% against 21.4%.

Range logged 2026-09-26, receipt 0d7b67fbe9081d9c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 1.05 Cybersecurity incident: 1, latest 2026-07-31 ([filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000119/0000318154-26-000119-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-27 ([filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000144/0000318154-26-000144-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000153/0000318154-26-000153-index.htm)
- 8-K · filed 2026-10-27 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000144/0000318154-26-000144-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000124/0000318154-26-000124-index.htm)
- 8-K · filed 2026-07-31 · 1.05 Material Cybersecurity Incidents · [filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000119/0000318154-26-000119-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000318154.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=318154

## Cite

POPS4, Edgar & Edgarette: Amgen Inc. (AMGN) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/AMGN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.